Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 2/20 | 0.77 |
| ▸ | TAF1 | P21675 | 3/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.42 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045544 | 0.87 | ZAP70 (1.00) | ZAP70LRRK2TTKMAPK10 | |
| SCHEMBL1047826 | 0.81 | ZAP70 (0.64) | ZAP70BRD4BTKCECR2 | |
| SCHEMBL1049582 | 0.81 | ZAP70 (0.73) | ZAP70BRD4CREBBPTTKJAK2 | |
| SCHEMBL1045612 | 0.81 | ZAP70 (0.73) | ZAP70BRD4TTKJAK2 | |
| SCHEMBL1048228 | 0.81 | ZAP70 (0.63) | ZAP70LRRK2TTKSYKPTK2 | |
| SCHEMBL1045623 | 0.77 | ZAP70 (0.80) | ZAP70TTKJAK2MAPK10 | |
| SCHEMBL1046587 | 0.76 | ZAP70 (0.66) | ZAP70LRRK2BRD4SYKJAK2 | |
| SCHEMBL1049683 | 0.74 | ZAP70 (0.76) | ZAP70LRRK2TTKMAPK10 | |
| SCHEMBL1047380 | 0.74 | ZAP70 (0.75) | ZAP70TTKSYKJAK2CCNC | |
| SCHEMBL1048934 | 0.73 | ZAP70 (0.67) | ZAP70LRRK2SYKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | claimed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885TAF1 4148/4885LRRK2 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.